Single-arm, Open-label, Dose-escalating Phase I Clinical Study of PA3-17 Injection in Children and Adolescents With Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics is advancing PA3-17 injection, a CAR-T therapy targeting CD7, into a Phase I clinical trial for pediatric and adolescent patients with relapsed/refractory T-ALL/T-LBL. The market for pediatric oncology therapies is expanding, driven by increasing incidences of hematological malignancies and a growing emphasis on targeted therapies. The competitive landscape includes established CAR-T therapies, such as Kymriah and Yescarta, which target different antigens. Successful outcomes in this trial could position PersonGen favorably in the CAR-T market, particularly in the underserved pediatric segment, enhancing its portfolio and potential for partnerships or acquisitions. Diligence should focus on regulatory pathways, safety profiles, and the ability to demonstrate superior efficacy compared to existing therapies.
Indication: CD7+ T-ALL/LBL
Modality: cell therapy
Target: CD7 chimeric antigen receptor (CAR) targeting T-lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)
Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD7 chimeric antigen receptor (CAR) targeting T-lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)
View original source fields
Condition raw: CD7+ T-ALL/LBL
Condition normalized: CD7+ T-ALL/LBL
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CD7 chimeric antigen receptor (CAR) targeting T-lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)
Target normalized: CD7 chimeric antigen receptor (CAR) targeting T-lymphoblastic leukemia/lymphoma (T-ALL/T-LBL)